SEARCH

SEARCH BY CITATION

References

  • 1
    Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960967.
    Direct Link:
  • 2
    Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 12211231.
  • 3
    Nasrallah SM, Willis CEJ, Galambos JT. Hepatic morphology in obesity. Dig Dis Sci 1981; 26: 325327.
  • 4
    Braillon A, Capron JP, Herve MA, Degott C, Quenum C. Liver in obesity. Gut 1985; 26: 133139.
  • 5
    Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450455.
  • 6
    Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity:an autopsy study with analysis of risk factors. HEPATOLOGY 1990; 12: 11061110.
  • 7
    Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 11031109.
  • 8
    Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease a feature of the metabolic syndrome. Diabetes 2001; 50: 18441850.
  • 9
    Day CP, James OFW. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998; 114: 842845.
  • 10
    Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 24672474.
    Direct Link:
  • 11
    Bedoucha M, Atzpodien E, Boelsterli UA. Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol 2001; 35: 1723.
  • 12
    Peterson KF, West AB, Reuben A, Rothman DL, Shulman GI. Noninvasive assessment of hepatic triglyceride content in humans with 13C nuclear magnetic resonance spectroscopy. HEPATOLOGY 1996; 24: 114117.
  • 13
    Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcohlic fatty liver disease. Gastroenterology 2002; 123: 745750.
  • 14
    Longo R, Pollesello P, Ricci C, Masutti F, Kvam BJ, Bercich L, et al. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging 1995; 5: 281285.
  • 15
    Hilden M, Christoffersen P, Juhl E, Dalgaard JB. Liver histology in a “normal” population—examination of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 1977; 12: 593597.
  • 16
    Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. HEPATOLOGY 1995; 22: 17141719.
  • 17
    Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann Intern Med 2000; 132: 112117.
  • 18
    Caldwell SH, Harris DM, Patrie JT, Hespenheide EE. Is NASH underdiagnosed among African Americans? Am J Gastroenterol 2002; 97: 14961500.
    Direct Link:
  • 19
    Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 2004; 99: 292298.
    Direct Link:
  • 20
    Szczepaniak LS, Leonard D, Browning JD, Nurenberg P, Reingold JS, Hobbs HH, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. Published online August 31, 2004, doi 10:1152/ajpendo.00064. 2004.
  • 21
    Victor RG, Haley RW, Willett D, Peshock RM, Vaeth PC, Leonard D, et al. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol 2004; 93: 14731480.
  • 22
    Institute for Survey Research. Technical Report for the 1995 National Alcohol Survey. Philadelphia, PA: Temple University, 1996.
  • 23
    Anonymous. Plan and Operation of the Third National Health and Nutrition Examination Survey. Washington, DC: National Center for Health Statistics, 1994.
  • 24
    Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 14871495.
  • 25
    Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539553.
  • 26
    Szczepaniak LS, Babcock EE, Schick F, Dobbins RL, Garg A, Burns DK, et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol Endocrinol Metab 1999; 276: E977E989.
  • 27
    Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 110.
  • 28
    Diehl AK, Poordad F. Nonalcoholic fatty liver disease. In: FeldmanM, FriedmanLS, Sleisenger, MH, eds. Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management. Volume 2. 7th ed. Philadelphia: Saunders, 2002: 13931400.
  • 29
    Thomsen C, Becker U, Winkler K, Christoffersen P, Jensen M, Henriksen O. Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging 1994; 12: 487495.
  • 30
    Longo R, Ricci C, Masutti F, Vidimari R, Croce LS, Bercich L, et al. Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography. Invest Radiol 1993; 28: 297302.
  • 31
    Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51: 797802.
  • 32
    Simha V, Szczepaniak LS, Wagner AJ, DePaoli AM, Garg A. Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. Diabetes Care 2003; 26: 3035.
  • 33
    Sanyal A. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 17051725.
  • 34
    Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population in Okinawa, Japan. Jpn J Med 1988; 27: 142149.
  • 35
    Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91100.
  • 36
    Facchini F, Chen YD, Reaven GM. Light-to-moderate alcohol intake is associated with enhanced insulin sensitivity. Diabetes Care 1994; 17: 115119.
  • 37
    Kiechl S, Willeit J, Poewe W, Egger G, Oberhollenzer F, Muggeo M, et al. Insulin sensitivity and regular alcohol consumption: large, prospective, cross sectional population study (Bruneck study). BMJ 1996; 313: 10401044.
  • 38
    Sato N, Lindros KO, Baraona E, Ikejima K, Mezey E, Jarvelainen HA, et al. Sex difference in alcohol-related organ injury. Alcohol Clin Exp Res 2001; 25: 40S45S.
  • 39
    Day CP, Yeaman SJ. The biochemistry of alcohol-induced fatty liver. Biochem Biophys Acta 1994; 1215: 3348.
  • 40
    Gholam PM, Kotler DP, Flancbaum LJ. Liver pathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg 2002; 12: 4951.
  • 41
    Caetano R. Alcohol-related health disparities and treatment-related epidemiological findings among whites, blacks, and Hispanics in the United States. Alcohol Clin Exp Res 2003; 27: 13371339.
  • 42
    Lelbach WK. Cirrhosis in the alcoholic and its relation to the volume of alcohol abuse. Ann N Y Acad Sci 1975; 252: 85105.
  • 43
    Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes:reversal of hepatic steatosis after sustained therapeutic response. HEPATOLOGY 2002; 36: 12661272.
  • 44
    McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999; 89: 1418.
  • 45
    Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556562.
  • 46
    Blatt LM, Mutchnick MG, Tong MJ, Klion FM, Lebovics E, Freilich B, et al. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepatol 2000; 7: 196202.
  • 47
    Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chretien Y, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002; 16: 185194.
  • 48
    Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34: 428434.
  • 49
    Seidell JC. Obesity, insulin resistance and diabetes—a worldwide epidemic. Br J Nutr 2000; 83: S5S8.